This CE-certified Web-based activity is based on information presented at a satellite
symposium held on December 7, 2010 in Anaheim, California at the 45th American
Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition.
Hardware/Software Requirements
- Javascript-enabled browser
- Active Internet connection
- Adobe Acrobat Reader
- Adobe Flash Player plugin v.8.0+
Activity Overview
Loss of bone mass, which leads to fracture and other complications, is increasingly recognized as a major health care dilemma. Currently, over 10 million Americans have been diagnosed with osteoporosis and an additional 34 million have low bone mass. The increased risk of bone loss and fracture that is seen throughout the course of disease in people with cancer is equally concerning. Bone loss in cancer patients is generally more rapid and severe than bone loss associated with aging and menopause. Bone metastasis also increases bone loss, further increasing risk. Skeletal-related events, especially pathologic fracture, lead to severe pain, a dramatic decrease in quality of life, and substantially increased rates of morbidity and mortality. To ensure optimal management of patients at risk for skeletal complications due to bone loss, pharmacists must have a thorough understanding of bone pathophysiology and the treatment strategies for bone loss. This activity features discussions on the current and emerging therapies used to manage patients with osteoporotic and cancer-related bone loss.
Target Audience
This activity has been designed to meet the educational needs of health-system pharmacists, retail pharmacists, and other pharmacy professionals involved in the management of patients with bone disease.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the impact of untreated bone loss on fracture risk, overall health, and
quality of life
- Recognize individuals at risk of bone loss and implement appropriate preventive
therapy early in the course of treatment
- Discuss mechanisms of bone loss and new therapeutic approaches to managing
bone loss
- Recommend appropriate screening methods and schedules to monitor for bone
loss
- Apply current guidelines in the prevention and management of bone disease
Faculty
Laura Boehnke Michaud, PharmD, BCOP, FASHP—Activity Chair
Manager, Clinical Pharmacy Services
The University of Texas M. D. Anderson Cancer Center
Adjunct Assistant Professor of Pharmacy Practice
University of Houston, College of Pharmacy
Houston, Texas
Jill S. Burkiewicz, PharmD, BCPS, FCCP
Professor, Pharmacy Practice
Director, PGY1 Residency Program
Midwestern University Chicago College of Pharmacy
Downers Grove, Illinois
Jane M. Pruemer, PharmD, BCOP, FASHP
Professor of Clinical Pharmacy Practice
James L. Winkle College of Pharmacy
University of Cincinnati Medical Center
Oncology Clinical Pharmacy Specialist
University Hospital and the Barrett Cancer Center
Cincinnati, Ohio
Sarah L. Scarpace, PharmD, BCOP
Assistant Dean for Pharmacy Professional Affairs
Albany College of Pharmacy and Health Sciences
Albany, New York
Accreditation Statement
Postgraduate Healthcare Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
UAN: 0430-0000-11-002-H01-P
Credits: 2.0 hours (0.20 ceu)
Type of Activity: Knowledge
Fee Information: There is no fee for this activity.
Method of Participation
There are no fees for participating in this CE activity. To receive credit during the period
January 26, 2011 to January 31, 2013, participants must (1) read the learning objectives and
disclosure statements, (2) study the educational activity, and (3) complete the posttest and
activity evaluation form, including the certificate information section.
To obtain a certificate, participants must receive a score of 70% or better on the posttest.
The posttest can be accessed at the end of the activity. Please e-mail any questions to
cecustomerservice@jobson.com.
Medium
This activity is offered as an Internet activity on the US Pharmacist Web site. Offering
this CE activity online allows participants to learn on their own time and at their own
pace. The interactive nature of the activity allows participants to become engaged and
offers visual, written, and spoken education to suit many learning styles.
Disclosure
In accordance with the Accreditation Council for Continuing Medical Education and
ACPE Standards for Commercial Support, all CME/CPE providers are required to
disclose to the activity audience the relevant financial relationships of everyone in a
position to control content of an educational activity. A relevant financial relationship is a
relationship in any amount occurring in the last 12 months with a commercial interest
whose products or services are discussed in the CE activity content over which the
individual has control. Relationship information appears below:
Jill S. Burkiewicz, PharmD, BCPS, FCCP, has disclosed no relevant financial
relationships.
Laura Boehnke Michaud, PharmD, BCOP, FASHP, has disclosed no relevant
financial relationships.
Dr. Michaud discusses the unlabeled or investigational use of a commercial product.
Jane M. Pruemer, PharmD, BCOP, FASHP, has disclosed no relevant financial
relationships.
Dr. Pruemer discusses the unlabeled or investigational use of a commercial product.
Sarah L. Scarpace, PharmD, BCOP, has disclosed the following relevant financial
relationships:
- Speaker - Merck, Millennium, Pfizer
Dr. Scarpace discusses the unlabeled or investigational use of a commercial product.
Curatio CME Institute
Matthew Horn, MD, Medical Director, has disclosed no relevant financial relationships.
Jonathan S. Simmons, ELS, Managing Editor, has disclosed no relevant financial
relationships.
Postgraduate Healthcare Education
Susanne Batesko, RN, BSN, President, has disclosed no relevant financial relationships.
Disclaimer
The information presented at this activity is for continuing pharmacy education purposes
only and is not meant to substitute for the independent medical judgment of pharmacists
regarding diagnosis and treatment of a specific patient’s medical condition.
Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses
of agents that are not indicated by the US Food and Drug Administration. Curatio CME
Institute, Postgraduate Healthcare Education, and Amgen do not recommend the use of
any agent outside the labeled indications.
The opinions expressed in this educational activity are those of the faculty and do not
necessarily represent the views of Curatio CME Institute, Postgraduate Healthcare
Education, or Amgen. Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Generic
Name |
Trade
Name |
Approved Use (if any) |
Unapproved/
Investigational Use |
| Anti-DKK1 |
N/A |
Investigational agent:
novel DKK1 inhibitor/Wnt
pathway stimulant |
Treatment and prevention of
bone metastasis; treatment and
prevention of cancer therapy–
induced bone loss |
| Atrasentan |
Xinlay |
Investigational agent:
novel endothelin-A
antagonist |
Treatment and prevention of
bone metastasis; treatment and
prevention of cancer therapy–
induced bone loss |
| AZD0530 |
N/A |
Investigational agent:
novel Src/Abl kinase
inhibitor |
Treatment and prevention of
bone metastasis |
Balicatib
(AAE-581) |
N/A |
Investigational agent:
novel cathepsin K inhibitor |
Treatment and prevention of
bone metastasis |
| Bortezomib |
Velcade |
Treatment of multiple
myeloma in patients who
have not responded to at
least one other agent |
Treatment and prevention of
bone metastasis; treatment and
prevention of cancer therapy–
induced bone loss |
| Clodronate |
Bonefos |
Treatment of hypercalcemia of
malignancy (outside the
United States; not
approved by the US FDA) |
Treatment and prevention of bone metastasis |
| Denosumab |
Prolia
Xgeva |
Treatment of osteoporosis
in postmenopausal women;
treatment of bone
metastasis from solid
tumors; not approved for
multiple myeloma |
Prevention of bone loss;
prevention of bone metastasis;
treatment and prevention of
cancer therapy–induced bone
loss |
| Ibandronate |
Boniva |
Treatment and prevention
of osteoporosis in
postmenopausal women |
Treatment and prevention of
bone metastasis |
| Ki26894 |
N/A |
Investigational agent:
novel transforming growth
factor-β kinase inhibitor |
Treatment and prevention of
bone metastasis |
| L-000845704 |
N/A |
Investigational agent:
novel integrin inhibitor |
Treatment and prevention of
bone metastasis |
Odanacatib
(MK-0822) |
N/A |
Investigational agent:
novel cathepsin K inhibitor |
Treatment and prevention of
bone metastasis; treatment and
prevention of cancer therapy–
induced bone loss |
| Pamidronate |
Aredia |
Treatment of Paget’s
disease, hypercalcemia of
malignancy, and the
osteolytic bone metastases
of multiple myeloma and
breast cancer
|
Prevention of bone metastasis;
treatment of bone metastasis in
prostate cancer; prevention and
treatment of cancer therapy–induced
bone loss |
Relacatib
(SB-462795)
|
N/A |
Investigational agent:
novel cathepsin K inhibitor
|
Treatment and prevention of
bone metastasis |
Zoledronic
acid
|
Reclast
Zometa
|
Treatment and prevention
of osteoporosis in
postmenopausal women;
treatment to increase bone
mass in men with
osteoporosis; treatment and
prevention of
glucocorticoid-induced
osteoporosis in patients
expected to be on
glucocorticoids for at least
12 months, treatment of
Paget’s disease; treatment
of hypercalcemia of
malignancy; multiple
myeloma; solid tumors
with documented
metastasis to bone (in
conjunction with standard
antineoplastic therapy);
prostate cancer that has
progressed after hormonal
therapy
|
Prevention of bone metastases;
treatment and prevention of
cancer therapy–induced bone
loss |